AAAAAA
Results: 1-25/30
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Knockout drug screens, NAT BIOTECH, 19(10), 2001, pp. 919-920
Authors:
Liu, AX
Rane, N
Liu, JP
Prendergast, GC
Citation: Ax. Liu et al., RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells, MOL CELL B, 21(20), 2001, pp. 6906-6912
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology, HIST HISTOP, 16(1), 2001, pp. 269-275
Authors:
Liu, AX
Cerniglia, GJ
Bernhardt, EJ
Prendergast, GC
Citation: Ax. Liu et al., RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage, P NAS US, 98(11), 2001, pp. 6192-6197
Authors:
Routhier, EL
Burn, TC
Abbaszade, I
Summers, M
Albright, CF
Prendergast, GC
Citation: El. Routhier et al., Human BIN3 complements the F-actin localization defects caused by loss of Hob3p, the fission yeast homolog of Rvs161p, J BIOL CHEM, 276(24), 2001, pp. 21670-21677
Authors:
DuHadaway, JB
Sakamuro, D
Ewert, DL
Prendergast, GC
Citation: Jb. Duhadaway et al., Bin1 mediates apoptosis by c-Myc in transformed primary cells, CANCER RES, 61(7), 2001, pp. 3151-3156
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Effects of farnesyltransferase inhibitors on cytoskeleton, cell transformation, and tumorigenesis - The FTI-Rho hypothesis, CANC DRUG, 8, 2001, pp. 159-169
Authors:
Prendergast, GC
Oliff, A
Citation: Gc. Prendergast et A. Oliff, Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects, SEM CANC B, 10(6), 2000, pp. 443-452
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects, CURR OP CEL, 12(2), 2000, pp. 166-173
Authors:
Elliott, K
Ge, K
Du, W
Prendergast, GC
Citation: K. Elliott et al., The c-Myc-interacting adaptor protein Bin1 activates a caspase-independentcell death program, ONCOGENE, 19(41), 2000, pp. 4669-4684
Authors:
Ge, K
Prendergast, GC
Citation: K. Ge et Gc. Prendergast, Bin2, a functionally nonredundant member of the BAR adaptor gene family, GENOMICS, 67(2), 2000, pp. 210-220
Authors:
Liu, AX
Du, W
Liu, JP
Jessell, TM
Prendergast, GC
Citation: Ax. Liu et al., RhoB alteration is necessary for apoptotic and antineoplastic responses tofarnesyltransferase inhibitors, MOL CELL B, 20(16), 2000, pp. 6105-6113
Authors:
Ge, K
Minhas, F
Duhadaway, J
Mao, NC
Wilson, D
Buccafusca, R
Sakamuro, D
Nelson, P
Malkowicz, SB
Tomaszewski, J
Prendergast, GC
Citation: K. Ge et al., Loss of heterozygosity and tumor suppressor activity of BIN1 in prostate carcinoma, INT J CANC, 86(2), 2000, pp. 155-161
Authors:
Ge, K
Duhadaway, J
Sakamuro, D
Wechsler-Reya, R
Reynolds, C
Prendergast, GC
Citation: K. Ge et al., Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity, INT J CANC, 85(3), 2000, pp. 376-383
Authors:
Liu, AX
Prendergast, GC
Citation: Ax. Liu et Gc. Prendergast, Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors, FEBS LETTER, 481(3), 2000, pp. 205-208
Authors:
Prendergast, GC
Du, W
Citation: Gc. Prendergast et W. Du, Targeting farnesyltransferase: is Ras relevant?, DRUG RESIST, 2(2), 1999, pp. 81-84
Authors:
Duhadaway, J
Rowe, F
Elliott, K
Mao, NC
Prendergast, GC
Citation: J. Duhadaway et al., Bau, a splice form of neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation, CELL AD COM, 7(2), 1999, pp. 99-110
Authors:
Basu, A
Rodeck, U
Prendergast, GC
Howe, CC
Citation: A. Basu et al., Loss of insulin-like growth factor I receptor-dependent expression of p107and cyclin A in cells that lack the extracellular matrix protein secreted protein acidic and rich in cysteine, CELL GROWTH, 10(11), 1999, pp. 721-728
Authors:
Elliott, K
Sakamuro, D
Basu, A
Du, W
Wunner, W
Staller, P
Gaubatz, S
Zhang, H
Prochownik, E
Eilers, M
Prendergast, GC
Citation: K. Elliott et al., Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms, ONCOGENE, 18(24), 1999, pp. 3564-3573
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Myc and Myb: are the veils beginning to lift?, ONCOGENE, 18(19), 1999, pp. 2914-2915
Authors:
Sakamuro, D
Prendergast, GC
Citation: D. Sakamuro et Gc. Prendergast, New Myc-interacting proteins: a second Myc network emerges, ONCOGENE, 18(19), 1999, pp. 2942-2954
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Mechanisms of apoptosis by c-Myc, ONCOGENE, 18(19), 1999, pp. 2967-2987
Authors:
Mao, NC
Steingrimsson, E
DuHadaway, J
Wasserman, W
Ruiz, JC
Copeland, NG
Jenkins, NA
Prendergast, GC
Citation: Nc. Mao et al., The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2, GENOMICS, 56(1), 1999, pp. 51-58
Authors:
Du, W
Lebowitz, PF
Prendergast, GC
Citation: W. Du et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB, MOL CELL B, 19(3), 1999, pp. 1831-1840
Authors:
Megyeri, K
Berencsi, K
Halazonetis, TD
Prendergast, GC
Gri, G
Plotkin, SA
Rovera, G
Gonczol, E
Citation: K. Megyeri et al., Involvement of a p53-dependent pathway in rubella virus-induced apoptosis, VIROLOGY, 259(1), 1999, pp. 74-84